Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

Article  CAS  PubMed  Google Scholar 

Andre T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.

Article  CAS  PubMed  Google Scholar 

Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. Ther Adv Vaccines Immunother. 2020;8:2515135520927164.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51.

CAS  PubMed  PubMed Central  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.

Article  CAS  PubMed  Google Scholar 

Mooradian MJ, Sullivan RJ. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Future Oncol. 2017;13:1649–63.

Article  CAS  PubMed  Google Scholar 

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin Drug Discov. 2021;16:391–410.

Article  CAS  PubMed  Google Scholar 

Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer. 2019;10:1031–5.

Article  PubMed  PubMed Central  Google Scholar 

Mansouri S, et al. Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. Front Oncol. 2023;13:1071751.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishio N, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74:5195–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chintala NK, et al. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. Front Immunol. 2023;14:1112960.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaufman HL, Shalhout SZ, Iodice G. Talimogene laherparepvec: moving from first-in-class to best-in-class. Front Mol Biosci. 2022;9:834841.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Todo T, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18:171–6.

Article  CAS  PubMed  Google Scholar 

Blanchette P, Teodoro JG. A renaissance for oncolytic adenoviruses? Viruses. 2023. https://doi.org/10.3390/v15020358.

Article  PubMed  PubMed Central  Google Scholar 

Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98:298–300.

Article  PubMed  Google Scholar 

Chen RF, Lee CY. Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection. Int Rev Immunol. 2014;33:45–53.

Article  PubMed  Google Scholar 

McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 2004;15:1022–33.

Article  CAS  PubMed  Google Scholar 

Li S, Ou M, Wang G, Tang L. Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy. Appl Microbiol Biotechnol. 2016;100:8325–35.

Article  CAS  PubMed  Google Scholar 

Niemann J, Kuhnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53:700–6.

Article  CAS  PubMed  Google Scholar 

Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of viral vectors for use in cardiovascular gene therapy. Viruses. 2010;2:334–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629.

Article  PubMed  PubMed Central  Google Scholar 

Lee M, et al. Targeting tumor neoangiogenesis via targeted adenoviral vector to achieve effective cancer gene therapy for disseminated neoplastic disease. Mol Cancer Ther. 2020;19:966–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bischoff JR, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–6.

Article  CAS  PubMed  Google Scholar 

Heise C, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6:1134–9.

Article  CAS  PubMed  Google Scholar 

Ramesh N, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor—armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12:305–13.

Article  CAS  PubMed  Google Scholar 

Bramante S, et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int J Cancer. 2015;137:1775–83.

Article  CAS  PubMed  Google Scholar 

Aiuti A, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007;14:1555–63.

Article  PubMed